South Dakota on Monday announced a statewide clinical trial of hydroxychloroquine in COVID-19 patients, the first in the nation to do a trial across an entire state.
Hydroxychloroquine is traditionally used against malaria, lupus, and rheumatoid arthritis but is approved for emergency use against COVID-19, the new disease caused by the CCP (Chinese Communist Party) virus, commonly known as novel coronavirus.
